Analysts: Potential blockbusters on the way
The US patent on best-selling drug Lexapro expired long ago and other crucial patent expirations are on the way for Lundbeck. Alzheimer drug Ebixa expires during H2 2013 and Cipralex is next in line in 2014. See which drugs could end up determining the future of the Danish company.
by Benjamin Werner Christensen
They are racing to beat each other to the finish line – the potential blockbusters in the pipeline of Lundbeck, the Danish pharmaceutical group specialising in the booming global market for neurological diseases.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
